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Why Precision Medicine?

Source: Schork (2015), Nature

The potential rewards of personalized medicine are great
“Right medicine at the right time for the right patient population”
Paradigm Shift, from traditional to personalized medicine…
Blockbuster “one size fits all” drug
 market for one
50%+ do not have favorable outcomes  smart prescribing
Adverse events, regardless of outcomes  minimize side effects
Types of Dx Innovation
Prognostic Dx Myriad BRACAnalysis® test assesses hereditary breast cancer risk;
Ariosa DNA-based blood test that screens for trisomy 21, 18 and 13
Monitoring Dx CareDx’s Allomap test, Google Smart Contact lens
Companion Dx Genentech-Roche: Herceptin – for HER2- positive breast cancer
Dx Tech/
Nanostring’s nCounter life science tool, Illumina sequencers, 10X
Services
Invitae aggregates many tests into a single catalog

The challenges associated with building a Dx business are also great
Cost Drivers
Technology

Revenue Drivers
Adoption

Science (trials, validation)

Reimbursement

FDA Regulation

Inefficiency of current Rx/Dx
(companion, monitoring diagnostics)

Partnerships, data sharing

Enforceability of IP (competition)

Some challenges are greater for Dx than Rx
Cost Drivers
Technology
Science (trials, validation)
FDA Regulation untested/charted
pathways
Partnerships, data sharing

Revenue Drivers
Adoption need to educate patients and
clinicians
Reimbursement challenging, one-time use
of many diagnostics
Inefficiency of current Rx/Dx (companion,
monitoring diagnostics)
Enforceability of IP (competition) IP
uncertainty

Rx profit margins of ~20% vs. Dx single digit margins

Innovation incentives have been depressed recently among several
dimensions (with some improvement)
Cost Drivers
Technology

Revenue Drivers
Adoption

Science (trials, validation)

CMS Reimbursement introduction of
clinical utility requirements ~2012, October
2015: CLFS price cuts

FDA Regulation July 2014: FDA
begins process of developing LDT
regulations
Partnerships, data sharing
Jan 2015: President’s Precision
Medicine initiative

Inefficiency of current Rx/Dx (companion,
monitoring diagnostics)
Enforceability of IP (competition) SCOTUS
Prometheus, Myriad, Akamai, Bilski, Alice,
Sequenom v. Ariosa,

Patents play a different role in Rx than in Dx, where the market is
underdeveloped and multiplex tests combine innovations
Dimension
Innovation

Traditional Rx
Chemical, biologic

Dx
Algorithmic, Multi-Actor,
Genetic
Product Profile
Single molecule
Trend towards multi-gene or
(blockbuster)
expression test panel
Validation Model FDA Clinical Trials
Variable based on class
Distribution
Pharmacy, OTC (small
CLIA-Qualified Laboratory
molecules)
(LDTs)
Revenue
“Drugs sell themselves.” Need to prove “better
Largely monopoly
outcome,” develop demand,
pricing.
payment scheme.

These factors impact different business models differently

DX Startup X

Myriad has successfully leveraged their data, relationships, and
increasingly diversified product line despite patent challenges…

SCOTUS
Decision

Non-invasive prenatal testing (NIPT) innovation is “one of the bright
spots”– more accurate + less invasive = rapid adoption

Companion diagnostics economics are compelling for drug companies at
the clinical test phase

Agarwal, Ressler, Snyder, 2015 (Pharmacogenomics and Personalized Medicine)

Reimbursement and adoption hurdles are chilling investment
in VC investment in prognostic diagnostics

Thus, while there is VC investment in some sectors, e.g. in diagnostic
imaging…

DX Startup X

…the incentives for certain forms of Dx innovation are depressed. Innovation
areas mentioned by interviewees:
- Venture-backed prognostic Dx. Costs and risks are too high, returns are
too uncertain.
- Companion Dx for generic Rx. Poor business case.
- Dx for conditions without molecular/genetic bases: immunology,
transplants, infections, cancer immunotherapy, autoimmune diseases.
Science isn’t there.

DX Startup X

Denying broad patentability on upstream correlations and methods impacts
different sorts of diagnostic companies differently
- Easier for technology companies to offer multiplex tests in the
absence of patent thickets
- Competition in tests reduce prices, increases access to tests, and
barriers to technological innovation
- Limited incentive to invest in new uses of existing drugs
- Harder to build a standalone prognostic diagnostic business based
on IP. Who will fund the next generation of Dx innovation and
development?

Policy interventions beyond patents to close the gaps?
#1: Reimbursement – improve, rationalize, stabilize the reimbursement
regimes
#2: Provide a cheaper faster path to validation and clinical utility
- Fund creation of big data sets, discovery and validation of correlations,
development, incentivize dataset sharing/collaboration (Price, Sachs)
#3: Carrots and sticks
- FDA priority review vouchers for certain neglected diagnostics (Sachs)
- Regulatory exclusivity (Sachs), coupled with disclosure of algorithms
(Price)
- FDA licensing requirements to facilitate sharing (Laakman), validation
bounty to encourage vetting of black-box medicine (Price)
- Orphan diagnostics?
References: Price, Cardozo L. Rev. (2015), Sachs, UC Davis L. Rev.(2015), Laakman, UCI L. Rev. (2015)

